The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.102%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: "Risky" Oil Price Rally Supports Stocks

Fri, 08th Apr 2016 11:10

LONDON (Alliance News) - Oil prices were again the main driver of the London stock market midday Friday, with equities tracking the commodity higher as traders anticipated next week's meeting of oil producers to discuss a freeze in production.

"A recovery in risk appetite on Friday that has seen funds flow out of bonds and back into equities can almost exclusively be laid at the feet of a rebound in the oil price," said Jasper Lawler, market analyst at CMC Markets.

However, Lawler said Friday's rebound in oil prices and equities is on "risky ground" as there is still an air of uncertainty whether an agreement on a freeze to oil supply can be reached by oil producers in the Doha meeting on April 17.

On several occasions Iran has ruled itself out of a freeze to production as it looks to regain market share after international sanctions on it were lifted. Last week, Saudi Arabia's deputy crown prince, Mohammed bin Salman, signalled in an interview with Bloomberg that if any country raises output, Saudi Arabia will follow suit. But then earlier this week Kuwait's OPEC governor said the meeting will deliver a freeze in output.

"Oil prices continue to get excited by the April 17 Doha meeting despite a chance of a production freeze deal looking slim to say the least with Iran saying 'No' and Saudi Arabia saying 'Only with Iran'. Desire is there, but as in break-up speak 'it's complicated'," said Accendo Markets head of research Mike van Dulken.

At midday, Brent oil traded at USD40.69 a barrel, higher than the USD38.93 a barrel at the London stock market close on Thursday. US benchmark West Texas Intermediate was at USD38.52 a barrel, compared to USD36.84 a barrel late Thursday.

The rise in oil prices was supporting shares in oil producers. Royal Dutch Shell 'A', up 2.1% and BP, up 2.1%, were both amongst the best performers in the FTSE 100.

The blue-chip index itself was up 0.7%, or 43.45 points, to 6,180.34. The FTSE 250 was up 0.6% to 16,821.17 points, and the AIM All-Share was up 0.2% at 718.46.

In Europe, the French CAC 40 index was up 0.8% and the German DAX 30 was up 0.9%.

Ahead of the open on Wall Street, futures pointed the Dow 30 up 0.5%, the S&P 500 up 0.6% and the Nasdaq 100 up 0.7%.

UK stocks and the pound remained resilient in the face of declining UK industrial output. Figures from the Office for National Statistics showed industrial output fell 0.3% month-on-month in February from January when it grew 0.2% and was below expectations for growth of 0.1%.

Manufacturing output dropped 1.1% on a monthly basis reversing a 0.5% rise in January and bigger than a 0.2% fall forecast by economists.

Whilst the pound took a hit from the data,that still left it at a similar level to that at the London equities open: USD1.4052 versus USD1.4050.

Shares in consumer credit reference agency Experian, down 1.8%, and asset manager Schroders, down 1.1%, were both hit by broker downgrades. HSBC cut Experian to Reduce from Buy, and Exane BNP cut Schroders to Neutral from Outperform.

FTSE 250-listed Vectura Group was up 4.1%. The respiratory pharmaceuticals company and Jordan-founded drug maker Hikma Pharmaceuticals said the new drug application for their fluticasone propionate and salmeterol inhalation powder was accepted for filing by the Food & Drug Administration in the US.

The pair are working together on the inhalation powder, which is a generic version of GlaxoSmithKline's Advair Diskus, used to treat asthma and maintain treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease. Hikma shares were up 0.6%, while Glaxo shares were flat.

Elementis was the worst performer in the FTSE 250, down 8.1% after Berenberg downgraded the company to Hold from Buy, citing "a full-looking valuation" and the "potential reduction in pricing and margins" within Elementis’s chromium division.

DFS Furniture was down 5.0% to 305.00 pence after private equity firm Advent International Corp said it agreed to sell a 14.1% stake in the sofa retailer for GBP90.0 million.

Advent agreed to sell 30.0 million shares at 300.00p per share to institutional investors, leaving the private equity firm with a 24.1% stake in DFS, held through 51.4 million shares. Settlement of the accelerated bookbuild placing is expected to take place on Tuesday next week, Advent said in a statement.

Digital audio content services company Immedia Group said it signed a new five-year service contract with an undisclosed global brand to provide a supply of branded in-store music and marketing channels.

Under the deal Immedia will provide services to the brand's operations in the UK and Europe, and provide in-store equipment to facilitate delivery of the service, in return for an annual subscription fee per site.

Additionally, Immedia will produce language specific marketing content at contract prices, and will supply its Dreamstream decoder products to stores subscribing to the service. The company's share price more than doubled in response to the news.

Pathfinder Minerals was the worst performer in the AIM All-Share down 35%. The miner said a court in Mozambique made a ruling against the company in its lengthy litigation process. The company wants to appeal the decision as it continues to try to reclaim numerous licenses.

Pathfinder has been fighting over the ownership of Companhia Mineira de Naburi SARL, that hold the licenses. It claimed the rights to the licences were illegally seized by General Jacinto Veloso and Diogo Cavaco and was hoping the court would rule Pathfinder validly acquired a 99.99% stake in Companhia Mineira.

Veloso and Cavaco, for their part, claimed Pathfinder failed to pay the USD10.0 million required under the option agreement in place to buy the shares, meaning these licences could not have been seized as Pathfinder never owned them.

Still ahead in the economic calendar, the National Institute of Economic and Social Research's UK gross domestic product estimate is at 1500 BST, and the Baker Hughes US oil rig count is due at 1800 BST.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
6 Mar 2023 09:48

LONDON BROKER RATINGS: DB cuts Reckitt; Jefferies likes Tesco

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
1 Mar 2023 09:52

LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
27 Feb 2023 09:38

Berenberg raises target price on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Read more
27 Feb 2023 09:26

LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
24 Feb 2023 09:37

LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
23 Feb 2023 09:54

Hikma Pharmaceuticals profit halves in 2022 on Generics impairment

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.

Read more
23 Feb 2023 09:02

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

Read more
23 Feb 2023 07:59

Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth

(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
22 Feb 2023 21:50

Hikma accuses Amarin of suppressing generic versions of heart pill

Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals

*

Read more
16 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Friday 17 February 
Allianz Technology Trust PLCFull Year Results
Kingspan Group PLCFull Year Results
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
Monday 20 February 
Bank of Cyprus Holdings PLCFull Year Results
Georgia Capital PLCFull Year Results
Goldplat PLCFull Year Results (TBC)
LungLife AI IncFull Year Results
Tristel PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 21 February 
Antofagasta PLCFull Year Results
BHP Group LtdHalf Year Results
Blancco Technology Group PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
HSBC Holdings PLCFull Year Results
InterContinental Hotels Group PLCFull Year Results
Safestore Holdings PLCTrading Statement
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Trifast PLCTrading Statement
Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
25 Jan 2023 09:33

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
18 Jan 2023 15:07

Director dealings: Hikma Pharmaceuticals director snaps up shares

(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.

Read more
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.